EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies

Tianrong Jia, Zehong Huang, Ningshao Xia iD, Quan Yuan

Viruses · 2026

DOI: 10.3390/v18060642 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2026. Verfasst von Tianrong Jia und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, School of Life Sciences, Xiamen U…. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, SARS-CoV-2, Antibodies, Viral, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 187 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The high-frequency mutation characteristics of SARS-CoV-2 have posed formidable challenges to the development of vaccines and therapeutic agents. Neutralizing antibodies, which serve as effective tools for prevention and control, have undergone continuous updates and iterations in response to viral mutations. This article provides a comprehensive review of researchers’ efforts to achieve both high neutralizing potency and high mutation tolerance in SARS-CoV-2–targeting neutralizing antibodies. Building on the characteristics of conventional antibodies directed against distinct epitopes on the S protein, it further discusses the research on nanobodies, antibody cocktails, multi-specific antibodies, and other antibody formats and engineering approaches, including artificial intelligence–enabled optimization. Each antibody-based strategy targeting SARS-CoV-2 has its own distinctive advantages and potential applications, providing an integrated perspective to support the continued development of antiviral neutralizing antibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, NeutralizingSARS-CoV-2Antibodies, ViralCOVID-19HumansSpike Glycoprotein, CoronavirusAnimalsEpitopesSingle-Domain AntibodiesProtein EngineeringMutation

Stichwörter der Autor:innen

SARS-CoV-2antibody cocktailsartificial intelligencebispecific antibodiesbroadly neutralizing antibodiesconserved epitopesnanobodies

Substanzen

Antibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2EpitopesSingle-Domain Antibodies

Autor:innen und Institutionen

  • State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, School of Life Sciences, Xiamen University, Xiamen 361102, China.
  • National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, National Innovation Platform for Industry-Education Integration in Vaccine Research…

ORCID-Profile: Ningshao Xia

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Jia, T., Huang, Z., Xia, N., & Yuan, Q. (2026). Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies. Viruses. https://doi.org/10.3390/v18060642

Vancouver

Jia T, Huang Z, Xia N, Yuan Q. Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies. Viruses. 2026. doi:10.3390/v18060642

BibTeX
@article{Jia2026,
  author = {Jia, Tianrong and Huang, Zehong and Xia, Ningshao and Yuan, Quan},
  title = {Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies},
  journal = {Viruses},
  year = {2026},
  doi = {10.3390/v18060642}
}
Kostenlos starten →